EP2618820A2 - Formulations d'opioïdes à libération contrôlée - Google Patents

Formulations d'opioïdes à libération contrôlée

Info

Publication number
EP2618820A2
EP2618820A2 EP11764653.9A EP11764653A EP2618820A2 EP 2618820 A2 EP2618820 A2 EP 2618820A2 EP 11764653 A EP11764653 A EP 11764653A EP 2618820 A2 EP2618820 A2 EP 2618820A2
Authority
EP
European Patent Office
Prior art keywords
oxycodone
salt
opioid
pharmaceutical formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11764653.9A
Other languages
German (de)
English (en)
Inventor
Edward M. Rudnic
Michael Vachon
Gary W. Pace
Joseph Berry
Felix De La Iglesia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QRxPharma Ltd
Original Assignee
QRxPharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/024,319 external-priority patent/US20110195989A1/en
Application filed by QRxPharma Ltd filed Critical QRxPharma Ltd
Publication of EP2618820A2 publication Critical patent/EP2618820A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques contenant des composants opioïdes qui possèdent chacun un profil de libération. Ces composants peuvent procurer une libération immédiate ou contrôlée de l'opioïde. L'invention a également trait à des procédés de régulation de la libération d'un ou de plusieurs composés opioïdes et à des méthodes de traitement de la douleur.
EP11764653.9A 2010-09-24 2011-09-23 Formulations d'opioïdes à libération contrôlée Withdrawn EP2618820A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38622710P 2010-09-24 2010-09-24
US13/024,319 US20110195989A1 (en) 2010-02-09 2011-02-09 Controlled Release Formulations of Opioids
PCT/US2011/053132 WO2012040651A2 (fr) 2010-09-24 2011-09-23 Formulations d'opioïdes à libération contrôlée

Publications (1)

Publication Number Publication Date
EP2618820A2 true EP2618820A2 (fr) 2013-07-31

Family

ID=44741728

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11764653.9A Withdrawn EP2618820A2 (fr) 2010-09-24 2011-09-23 Formulations d'opioïdes à libération contrôlée

Country Status (6)

Country Link
EP (1) EP2618820A2 (fr)
JP (1) JP2013537915A (fr)
CN (1) CN103476403A (fr)
AU (1) AU2011305161A1 (fr)
CA (1) CA2812570A1 (fr)
WO (1) WO2012040651A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme de liberation a base de polymere
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP1610767B1 (fr) 2003-03-26 2011-01-19 Egalet A/S Systeme de liberation regulee de morphine
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2393484A1 (fr) 2009-02-06 2011-12-14 Egalet Ltd. Composition à libération immédiate résistant à une maltraitance par prise d'alcool
CA2766179A1 (fr) 2009-06-24 2010-12-29 Egalet Ltd. Formulations a liberation controlee
AU2013204592A1 (en) * 2012-04-09 2013-10-24 QRxPharma Ltd. Controlled release formulations of opioids
EP2877161A1 (fr) 2012-07-06 2015-06-03 Egalet Ltd. Compositions pharmaceutiques de dissuasion d'abus à libération contrôlée
WO2016010771A1 (fr) * 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
CN114515282B (zh) * 2020-11-19 2023-09-08 山东大学 Sorbic acid在制备抗冠状病毒感染药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US20030125347A1 (en) * 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
WO2006073396A1 (fr) 2005-01-05 2006-07-13 Regents Of The University Of Minnesota Conjugues analgesiques
CN101151021A (zh) * 2005-03-28 2008-03-26 奥瑞克索股份公司 用于疼痛治疗的新药物组合物
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
CN101534827A (zh) * 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药
US20090291975A1 (en) * 2008-05-20 2009-11-26 Warren Stern Dual opioid pain therapy
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012040651A2 *

Also Published As

Publication number Publication date
AU2011305161A1 (en) 2013-05-09
CN103476403A (zh) 2013-12-25
CA2812570A1 (fr) 2012-03-29
WO2012040651A3 (fr) 2012-05-18
WO2012040651A2 (fr) 2012-03-29
JP2013537915A (ja) 2013-10-07

Similar Documents

Publication Publication Date Title
US20110195989A1 (en) Controlled Release Formulations of Opioids
US20130022646A1 (en) Controlled Release Formulations of Opioids
WO2012040651A2 (fr) Formulations d'opioïdes à libération contrôlée
JP5844312B2 (ja) 事故的誤用および不法転用を防止するための耐破砕性錠剤
RU2599846C2 (ru) Новые и эффективные лекарственые формы тапентадола
CN105534936B (zh) 抗滥用药物、使用方法和制备方法
AU657027B2 (en) Controlled release oxycodone compositions
JP4425093B2 (ja) 血漿中の薬物レベルの初期上昇速度が急速な２４時間経口オピオイド製剤の投与による、疼痛の治療方法
JP6550157B2 (ja) Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
IL235150A (en) Pharmaceuticals
SG172818A1 (en) Abuse resistant melt extruded formulation having reduced alcohol interaction
FR2892937A1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
AU3687701A (en) Controlled-release compositions containing opioid agonist and antagonist
MXPA04001210A (es) Formulaciones de agonista opioide con antagonista liberable y aislado.
NO323574B1 (no) Multippelenhets doseringsmateriale for modifisert avgivelse
EP2219612A1 (fr) Formulation à libération contrôlée évitant les utilisations impropres
AU2012347200A1 (en) Tablet capable of combatting misuse by injection
EP2224808A2 (fr) Composition pharmaceutique
WO2013153451A2 (fr) Formulations d'opioïdes à libération contrôlée
AU2018219999A1 (en) Pharmaceutical composition
AU2014216026A1 (en) Pharmaceutical composition
AU2012202717A1 (en) Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130423

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160401